We’re now about one month away from the end of the hospital-at-home waiver that has been keeping the program alive. With the March 31 deadline fast ...

Ionis Pharmaceuticals, Inc. today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension ...